

[First Reprint]

SENATE, No. 834

STATE OF NEW JERSEY
218th LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION

Sponsored by:

Senator NICHOLAS P. SCUTARI

District 22 (Middlesex, Somerset and Union)

Senator LINDA R. GREENSTEIN

District 14 (Mercer and Middlesex)

Assemblywoman PATRICIA EGAN JONES

District 5 (Camden and Gloucester)

Assemblywoman ELIANA PINTOR MARIN


District 29 (Essex)

SYNOPSIS

Prohibits resale of non-prescription diabetes test devices by pharmacists.

CURRENT VERSION OF TEXT

As amended on January 9, 2020 by the Senate pursuant to the Governor's recommendations.



(Sponsorship Updated As Of: 6/21/2019)

1 AN ACT concerning non-prescription diabetes test devices and
2 supplementing Title 45 of the Revised Statutes.

3
4 **BE IT ENACTED** by the Senate and General Assembly of the State
5 of New Jersey:

6
7 1. As used in this act:

8 “Board” means the New Jersey State Board of Pharmacy
9 established pursuant to P.L.2003, c.280 (C.45:14-40 et seq.)

10 “Non-prescription diabetes test device” means a glucose meter or
11 test strip for use in the treatment of prediabetic or diabetic
12 individuals that may be sold without a prescription and that is
13 labeled for use by the consumer in accordance with applicable State
14 and federal law.

15
16 2. ¹a.¹ A manufacturer of a non-prescription diabetes test
17 device that is distributed within New Jersey shall make the names
18 of its authorized distributors available on its Internet Web site
19 ¹and shall provide the board with the names of its authorized
20 distributors. Within 30 days of receiving that information from a
21 manufacturer of a non-prescription diabetes test device, the board
22 shall post the names of authorized distributors of non-prescription
23 diabetes test devices on the board’s Internet Web site¹. A
24 manufacturer of a non-prescription diabetes test device shall, within
25 30 days of making a change to its authorized distributors, update its
26 Internet Web site ¹and inform the board of to reflect any¹
27 changes to its authorized distributors. ¹Within 30 days of
28 receiving notice of any change from a manufacturer of a non-
29 prescription diabetes test device, the board shall post the updated
30 list of the manufacturer’s authorized distributors on its Internet Web
31 site]

32 b. It shall be an unlawful practice and a violation of P.L.1960,
33 c.39 (C.56:8-1 et seq.) for any retail mercantile establishment to sell
34 or offer to sell to a consumer in New Jersey a non-prescription
35 diabetes test device that was not acquired directly from the
36 manufacturer or from one of the manufacturer’s authorized
37 distributors, unless the device is plainly marked by a stamp, tag,
38 label or sign that is either affixed to the device or located at the
39 point of sale disclosing that the device was not acquired directly
40 from the manufacturer or from an authorized distributor of the
41 manufacturer.

42 c. It shall be an unlawful practice and a violation of P.L.1960,
43 c.39 (C.56:8-1 et seq.) for any retail mercantile establishment to sell

EXPLANATION – Matter enclosed in bold-faced brackets [thus] in the above bill is
not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

Matter enclosed in superscript numerals has been adopted as follows:

¹Senate amendments adopted in accordance with Governor's
recommendations January 9, 2020.

1 or offer to sell to a consumer in New Jersey a non-prescription
2 diabetes test device that was previously sold and repackaged, unless
3 the device is plainly marked by a stamp, tag, label or sign that is
4 either affixed to the device or located at the point of sale disclosing
5 that the device was previously sold and re-packaged.

6 d. For the purposes of this section, a “retail mercantile
7 establishment” means any place of business where merchandise is
8 exposed or offered for sale at retail to members of the public. This
9 term shall include entities that use the Internet or other electronic
10 means to expose or offer merchandise for sale at retail to consumers
11 in New Jersey¹ .

12
13 3. In addition to the responsibilities given to the board pursuant
14 to the “New Jersey Pharmacy Practice Act,” P.L.2003, c.280
15 (C.45:14-40 et seq.), the board shall require that a pharmacy that
16 dispenses non-prescription diabetes test devices pursuant to
17 prescriptions shall retain records of its acquisition, inventory, and sale
18 of those non-prescription diabetes test devices. The records shall be
19 maintained in a manner prescribed by the board by regulation, and
20 shall be retained for a period of not less than three years. The board
21 shall have authority to inspect records at all reasonable hours.

22
23 ¹4. The board may embargo any non-prescription diabetes test
24 device that a board inspector finds or has probable cause to believe
25 was not purchased either directly from the manufacturer or from the
26 non-prescription diabetes test device manufacturer’s authorized
27 distributors as identified in section 2 of P.L. , c. (C.)
28 (pending before the Legislature as this bill). Procedures for
29 embargoing of such devices shall be established by the board by
30 regulation pursuant to the “Administrative Procedure Act,”
31 P.L.1968, c.410 (C.52:14B-1 et seq.), consistent with the
32 requirements of subsection c. of section 9 of P.L.2003, c.280
33 (C.45:14-48).¹

34
35 ¹5. ¹4. ¹ A pharmacist who ¹5. ¹ submits a reimbursement claim
36 for ¹5. ¹ sells, offers for sale, or otherwise dispenses to the public¹ a
37 non-prescription diabetes test device ¹5. ¹ to a health insurance carrier,
38 pharmacy benefit manager, government agency, or other third-party
39 payer when ¹5. ¹ that¹ the pharmacist ¹5. ¹ knew¹ knows¹ or reasonably
40 should have known ¹5. ¹ that the pharmacy did not purchase the
41 diabetes test device ¹5. ¹ was not acquired by the pharmacy¹ either
42 directly from the manufacturer or from one of the manufacturer’s
43 authorized distributors ¹5. ¹ identified pursuant to section 2 of P.L. ,
44 c. (C.) (pending before the Legislature as this bill)¹ shall be
45 subject to disciplinary action pursuant to section 8 of P.L.1978, c.73
46 (C.45:1-21).

1 ¹**[6.] 5.**¹ The New Jersey State Board of Pharmacy shall, in
2 accordance with the “Administrative Procedure Act,” P.L.1968,
3 c.410 (C.52:14B-1 et seq.), adopt any rules and regulations as the
4 board deems necessary to carry out the provisions of this act.

5

6 ¹**[7.] 6.**¹ This act shall take effect on the first day of the
7 seventh month next following the date of enactment.